LINX® more effective than Omeprazole at controlling regurgitation and improving quality of life in patients with Gastroesophageal Reflux Disease (GERD)

May 24, 2017 via Torax Medical, Inc.

The CALIBER Trial is a multi-center randomized controlled trial comparing LINX to acid suppression medication (omeprazole) in patients with troublesome regurgitation.  All patients had a diagnosis of GERD as confirmed by abnormal acid exposure time and moderate to severe regurgitation despite taking once-daily omeprazole.  Patients were randomized to treatment with twice a day omeprazole or LINX.  The primary endpoint of the trial was elimination of moderate to severe regurgitation at 6 months after treatment.  Preliminary results reported at DDW showed*:

  • 92.6% of patients treated with LINX achieved the primary endpoint success criteria versus 8.6% of patients treated with twice a day omeprazole.
  • Significant improvement in quality of life was achieved in 88.9% of patients treated with LINX versus 6.8% of patients treated with twice a day omeprazole.
  • Normal levels of reflux were restored in 92% of patients treated with LINX compared to 36% of patients treated with twice a day omeprazole.

*This data was presented at Digestive Disease Week 2017 (DDW) in Chicago, IL, by Dr. Reginald Bell, SurgOne Foregut Institute, Englewood, CO

View Full Story

View Indications, Safety and Warnings

Would you like Torax Medical to send information on LINX to the doctor currently treating your reflux disease?

  • Lorem can't be blank
  • Lorem can't be blank

The information provided on this website is not medical advice and is intended for educational purposes only. Talk to a doctor if you have concerns about your health. Call 911 in the event of a medical emergency. Please do not submit medical information to this website or request treatment advice. For more information about the benefits and risks of LINX please click here.

Message Sent!

Thank you for your submission.
We will be in contact with your doctor.